PharmaReview provides copy review services to the life science industry. Copy review is an important and time-consuming job for thousands of professionals. We ensure that materials, whether internal or external, promotional or non-promotional, are ready for internal review and rapid progression to certification.
From April 2021 to April 2022 we have grown our team from 20 to 60 employees, and continue to recruit.
PharmaReview’s partnership with Bridgepoint Growth
By late 2020, PharmaReview’s founders, Ralph Carter and Tessa Pugh, had seen the business grow into the acknowledged leader in its field. With the 10th anniversary approaching it was clear that the logical next stage in expansion - to fully extend the company’s reach internationally - would require external expertise and investment, and the decision was taken to partner with private equity specialists Bridgepoint Growth.
Bridgepoint’s track record in the pharmaceutical sector, which included investments in Quotient Clinical and Phlexglobal, made it the obvious choice and by mid-2021 negotiations were complete and the partnership was in place.
For further information:
Bridgepoint is an international alternative asset management firm. With over €32 billion of assets under management, it is currently focused on private equity and private debt:
- Its private equity funds typically focus on investing in well managed companies in attractive sectors; helping companies and management teams by investing in expansion, operational transformation or via consolidating acquisitions;
- Its private debt activities are implemented by Bridgepoint Credit which invests across the capital structure through three complementary strategies - direct lending, credit opportunities and senior debt.
Bridgepoint has offices in Amsterdam, Frankfurt, London, Luxemburg, Madrid, New York, Paris, San Francisco, Shanghai and Stockholm.